| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 15:46 | Novartis targets undruggable cancers with $1.9bn Antares Therapeutics deal | ||
| 12:46 | OURA and Lilly join forces to harmonise drug-wearable obesity care | ||
| 11:46 | Boehringer and Combotope partner for cancer antibodies | ||
| 10:46 | Haisco and Nuvectis sign licensing deal for two drugs | ||
| Di | BIO 2026: NVIDIA announces the BioNeMo toolkit for AI agents | ||
| Di | FDA changes rare disease tune again as it clears path for Regenxbio's gene therapy | ||
| Di | Genprex's Reqorsa combo secures Canadian patent for lung cancer | ||
| Di | BIO 2026: Drug manufacturers band together to tackle employment challenges | ||
| Di | Lilly and BioArctic sign deal to develop neurodegenerative therapy | ||
| Mo | AbbVie deepens immunology legacy in $10.9bn Apogee buyout | ||
| Mo | HLTH Europe 2026: enriching the patient journey with health technologies | ||
| Mo | Moderna's mRNA flu vaccine passes FDA AdCom, review underway | ||
| Mo | Moderna's mRNA flu vaccine set for FDA review after positive AdCom | ||
| Mo | Sun Pharma to acquire Innovcare Lifesciences for $28.7m | ||
| Mo | Japan approves Sanofi's Sarclisa combo for MM treatment | ||
| Fr | Biopharma industry confidence at highest in years despite geopolitical headwinds | ||
| Fr | Voro and Alloy partner on tumour-selective TCE therapeutics | ||
| Fr | Biogen to acquire RayThera for up to $1bn | ||
| Do | UniQure to seek approval of Huntington's gene therapy after FDA U-turn | ||
| Do | Jazz and AbCellera sign deal for T-cell engagers in solid tumours | ||
| Do | LG AI Research and D&D Pharmatech sign agreement for oral peptide drugs | ||
| 17.06. | Biopharma bounces back as M&A impetus fuels recovery | ||
| 17.06. | Vedana debuts with $46m to progress migraine therapies | ||
| 17.06. | AviadoBio broadens vMiX gene silencing licence with King's College London | ||
| 17.06. | Altaris to acquire Simulations Plus in $375m all-cash deal |